Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page
- Check6 days agoChange DetectedRecruitment status is updated to indicate no ongoing participant enrollment. The page adds new help and navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label, along with a revision note to v3.6.0 (replacing v3.5.5).SummaryDifference0.6%

- Check13 days agoChange DetectedFooter revision updated from v3.5.4 to v3.5.5, indicating a page rendering update that does not modify the clinical trial details or study data.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedA new Revision label (v3.5.4) appears, replacing the previous v3.5.3. This reflects a minor product update to the page interface without altering study information.SummaryDifference0.1%

- Check56 days agoChange DetectedClinicalTrials.gov updated the page’s revision label from v3.5.2 to v3.5.3, indicating a site/version refresh rather than a change to the study record content.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.